Malaria Treatment (United States)
- Treatment of Malaria: Parts 1–3 Cdc-pdf[PDF, 177 KB, 8 pages]
- Treatment of Malaria, Part 1: Reporting and Evaluation & Diagnosis
- Treatment of Malaria, Part 2: Treatment: General Approach to Treatment and Treatment of Uncomplicated Malaria
- Treatment of Malaria, Part 3: Alternatives for Pregnant Women and Treatment of Severe Malaria
- Treatment Algorithm: Treatment summary in decision tree form Cdc-pdf[PDF, 117 KB, 1 page]
- Treatment Guidelines Table: Treatment summary in table format (Updated April 2019) Cdc-pdf[PDF, 100 KB, 3 pages]
Malaria can be a severe, potentially fatal disease (especially when caused by Plasmodium falciparum) and treatment should be initiated as soon as possible.
Patients who have severe malaria or who cannot take oral medications should be given the treatment by continuous intravenous infusion.
Most drugs used in treatment are active against the parasite forms in the blood (the form that causes disease) and include the following:
- Atovaquone-proguanil (Malarone®)
- Artemether-lumefantrine (Coartem®)
- Doxycycline (used in combination with quinine)
- Clindamycin (used in combination with quinine)
- Tetracycline (used in combination with quinine)
- Artesunate (not licensed for use in the United States, but available through CDC)
In addition, primaquine and tafenoquine are active against the dormant parasite liver forms (hypnozoites) and prevent relapses. Primaquine and tafenoquine should not be taken by pregnant women or by people who are deficient in G6PD (glucose-6-phosphate dehydrogenase). Patients should not take primaquine or tafenoquine until a quantitative test has excluded G6PD deficiency.
How to treat a patient with malaria depends on:
If you have had a serious side effect while taking a drug, you or your health care provider can report that side effect to the federal Food and Drug Administration (FDA). MedWatch is the FDA Safety Information and Adverse Event Reporting Program. You are encouraged to take the reporting formExternal to your health care provider.
Alternatively, health care providers can report to the FDA.
- Online www.accessdata.fda.gov/scripts/medwatch/External
- By phone (1-800-FDA-1088)
- or fax (1-800-FDA-0178)
The advantage to having your health care provider file the report is that he/she can provide clinical information based on your medical record that can help the FDA evaluate the report.
However, for a variety of reasons, you may not wish to have the form completed by your provider, or the provider may not wish to complete the form. Your health care provider is not required to report to the FDA. In this case, you may complete the online reporting form at www.fda.gov/medwatch/report/consumer/consumer.htmExternal yourself via the Internet.